List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Paris-based One Biosciences, a precision oncology biotech company, has raised €15 million in Series A financing to accelerate the development of its AI-powered single-cell tumour profiling platform.
A new international framework introduces rigorous validity standards for the use of brain organoids and iPSC-derived models in studying neuropsychiatric disorders. These guidelines aim to accelerate drug discovery and bring precision treatments closer to reality.
A new stroke treatment, GAI-17, developed by researchers in Japan, has shown encouraging results in reducing brain cell death and paralysis in animal models – potentially allowing for future development of treatments for other brain disorders.
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
A new preclinical study has combined two experimental drugs that effectively block ovarian tumour growth – a strategy that could lead to new treatments against this genetically complex cancer.
A new dual CAR-T cell therapy targeting two tumour-specific proteins in T-cell Acute Lymphoblastic Leukaemia (T-ALL) has been developed – meaning effective treatment for this aggressive blood cancer could soon become a reality.
Researchers in Japan have developed long-lasting 3D liver organoids from stem cells by incorporating bile acids into the culture medium - offering a new model for studying chronic liver diseases.
Scientists at Lund University have shown that aggressive melanoma tumours are driven by overactive mitochondrial processes – revealing a potential treatment strategy using drugs already approved for other conditions.
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 1, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
Single-cell and spatial technologies are giving researchers an unprecedented view of how brain diseases like Alzheimer’s really work. The result? Faster discovery, clearer targets and a new path towards more effective treatments.
Researchers at the University of Basel and Roche have discovered that slowing the intracellular transport of RNA-based drugs significantly improves their therapeutic impact.
Drug Target Review spoke with Giancarlo Basile at SLAS Europe 2025 about MGI’s bold shift from sequencing specialist to automation partner – helping research companies of all sizes achieve accuracy, speed and reproducibility.
AI will not replace drug discovery, but it might finally fix one of its most frustrating bottlenecks. Read how a targeted approach to ADMET is cutting through the noise.
Researchers at Tel Aviv University have developed a new mouse model that accurately mimics a rare and severe genetic disorder caused by mutations in the GRIN2D gene – allowing for study of the disease’s progression and the testing of potential drug therapies.
